Neurodegeneration & Alzheimer Risk Panel – Serum

Beschrijving

Clinical purpose

This panel provides a blood-based assessment of neurodegeneration and Alzheimer’s disease risk, using validated serum biomarkers associated with amyloid pathology, tau pathology, and genetic susceptibility.

It is intended for individuals with:

• Memory complaints or cognitive changes
• Mild cognitive impairment (MCI)
• Family history of Alzheimer’s disease
• Preventive or early risk evaluation
• Clinical follow-up of neurodegenerative risk

Biomarkers included (serum)

Amyloid pathology

• β-Amyloid 42 / 40 ratio
  Indicator of cerebral amyloid deposition risk

Tau pathology

• Phosphorylated Tau (p-Tau 181)
  Marker of neurodegeneration and disease progression
• Phosphorylated Tau (p-Tau 217)
  High specificity marker for Alzheimer-type pathology

Genetic risk (optional add-on)

• APOE Genotype (E2 / E3 / E4)
  Genetic susceptibility profiling
  (Requires informed consent)

Sample & methodology

• Sample type: Serum (venous blood)
• Analytical methods: High-sensitivity immunoassays / LC-based platforms
• Turnaround time: Approximately 10–15 working days
• Transport: Standard serum shipment

Clinical interpretation note

This panel supports risk stratification and clinical insight into neurodegenerative processes. It does not replace neurological evaluation, imaging, or formal cognitive testing and should always be interpreted in clinical context.

Why this panel matters

• Blood-based alternative to CSF testing
• Suitable for early detection and preventive strategies
• Clinically aligned with emerging Alzheimer diagnostics
• Practical for routine clinical and private testing

Suitable for postal submission.